Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061412 | 0.84 | FDPS (0.49) | ADORA2AADORA1ADCY5CYP1A2TSHR | |
| SCHEMBL7812370 | 0.83 | ADORA2A (0.63) | ADORA2AADORA1ADCY5CYP1A2TSHR | |
| SCHEMBL10362340 | 0.82 | ADORA2A (0.61) | ADORA2AADORA1ADCY5CYP1A2TSHR | |
| SCHEMBL13668183 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1ADCY5CYP1A2TSHR | |
| SCHEMBL10889158 | 0.78 | ADORA2A (0.68) | ADORA2AADORA1CYP1A2TSHRCYP2D6 | |
| SCHEMBL14028468 | 0.74 | ADORA2A (0.59) | ADORA2AADORA1CYP1A2TSHRADORA2B | |
| SCHEMBL6060863 | 0.73 | HPRT1 (0.65) | — | |
| SCHEMBL10532237 | 0.73 | ADCY5 (0.46) | ADORA2AADORA1ADCY5CYP1A2TSHR | |
| SCHEMBL6013391 | 0.73 | ADORA2A (0.64) | ADORA2AADORA1CYP1A2TSHRCYP2D6 | |
| SCHEMBL28770510 | 0.73 | ADORA2A (0.47) | ADORA2AADORA1CYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060228305-A1 | Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | US | disclosed |
| EP-1592422-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS OF TNF ALPHA SYNTHESIS OR ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004071383-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS OF TNF ALPHA SYNTHESIS OR ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-0767793-B1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | UNIV NORTH CAROLINA (US) | 2002-09-18 | — | — | EP | disclosed |
| US-5643893-A | ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | MACRONEX, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0767793-A1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1995035300-A1 | N-SUBSTITUTED-(DIHYDROXYBORYL)ALKYL PURINE, INDOLE AND PYRIMIDINE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228305-A1 | Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action | CHRNA1, CHRNG, CHRNB1 | ADORA2A 986/4885ADORA1 229/4885ADCY5 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.